New shingles vaccine CRV-101 takes on shingrix in Head-to-Head trial
Vaccine
Ongoing
This phase 2 study tests a new shingles vaccine called CRV-101 (amezosvatein) against the current standard, Shingrix, in about 1,500 adults aged 50 and older. The goal is to see if CRV-101 is safer and triggers a strong immune response. Participants receive two shots and are moni…
Phase 2 • Sponsor: Curevo Inc • Aim: Vaccine
Last updated Jun 27, 2026 07:53 UTC